Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). (SURTAVI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01586910
Recruitment Status : Active, not recruiting
First Posted : April 27, 2012
Last Update Posted : April 27, 2018
Information provided by (Responsible Party):
Medtronic Cardiovascular

Brief Summary:

The purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients to either Surgical Aortic Valve Replacement (SAVR) or TAVI with the Medtronic CoreValve® System.

Single Arm: The purpose of this trial is to evaluate the safety and effectiveness of transcatheter aortic valve implementation (TAVI) in patients with sever symptomatic Aortic Stenosis (AS) at intermediate surgical risk with TAVI. This is a non-randomized phase of the pivotal clinical trial.

Condition or disease Intervention/treatment Phase
Severe Aortic Stenosis Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) Procedure: Surgical Aortic Valve Replacement (SAVR) (Not applicable for Single Arm) Device: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI) Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)
Actual Study Start Date : April 2012
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : November 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Medtronic CoreValve® System TAVI
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device: Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Active Comparator: SAVR
Surgical Aortic Valve Replacement (SAVR) (Not applicable for Single Arm)
Procedure: Surgical Aortic Valve Replacement (SAVR) (Not applicable for Single Arm)

Primary Outcome Measures :
  1. All-cause mortality or disabling stroke [ Time Frame: 24 months ]
    All-cause mortality or disabling stroke

Secondary Outcome Measures :
  1. Incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) [ Time Frame: 5 years ]

  2. The occurrence of individual MACCE components [ Time Frame: 5 years ]
  3. Major Adverse Events (MAE) [ Time Frame: 5 years ]
  4. Conduction disturbance requiring permanent pacemaker implantation [ Time Frame: 5 years ]
  5. Change in NYHA class from baseline [ Time Frame: Baseline through 5 years ]
  6. Change in distance walked during 6-minute walk test (6MWT) [ Time Frame: Baseline through 24 months ]
  7. Ratio of days alive out of hospital versus total days alive [ Time Frame: 12 and 24 months ]
  8. Quality of Life (QoL) change from baseline [ Time Frame: Baseline through 5 years ]
  9. Echocardiographic assessment of prosthetic valve performance [ Time Frame: 5 years ]
    Measured by transvalvular mean gradient, effective orifice area and degree of prosthetic aortic valve regurgitation (transvalvular and paravalvular)

  10. Aortic valve disease related hospitalizations [ Time Frame: 5 years ]
  11. Cardiovascular deaths and valve-related deaths [ Time Frame: 5 years ]
  12. Stroke and TIAs [ Time Frame: 5 years ]
  13. Peri-procedural neurological injury [ Time Frame: 5 years ]
  14. Index procedure related major adverse events (MAEs) [ Time Frame: Number of days from admission to discharge (expected average of 7 days) ]
  15. Length of index procedure hospital stay [ Time Frame: Number of days from admission to discharge (expected average of 7 days) ]
  16. Presence of atrial fibrillation [ Time Frame: 5 years ]
  17. Device success (Medtronic CoreValve® System subjects only) [ Time Frame: Number of days from admission to discharge (expected average of 7 days) ]
    Device success

  18. Procedural success (Medtronic CoreValve® System subjects only) [ Time Frame: Number of days from admission to discharge (expected average of 7 days) ]
    Defined by device success and absence of in-hospital major adverse cardiovascular and cerebrovascular events (MACCE)

  19. Evidence of prosthetic valve dysfunction (Medtronic CoreValve® System subjects only) [ Time Frame: 5 years ]
  20. Incidence of Early Safety [ Time Frame: 30 Days ]
    Incidence of Early safety at 30 days

  21. Incidence of Clinical Efficacy (after 30 days) [ Time Frame: 5 years ]
    Clinical efficacy

  22. Incidence of Time-Related Safety [ Time Frame: 5 years ]
    Time-Related Safety

  23. Resheath and recapture scuccess (Evolut R only) [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must have co-morbidities such that Heart Team agrees predicted risk of operative mortality is ≥3% and <15% at 30 days (Intermediate Clinical Risk classification). Heart team evaluation of clinical surgical mortality risk for each patient includes the calculated STS score for predicted risk of surgical mortality augmented by consideration of the overall clinical status and co-morbidities unmeasured by the STS risk calculation;
  • Heart Team unanimously agree on treatment proposal and elgibility for randomization* based on their clinical judgement (including anatomy assessment, risk factors, etc.);
  • Subject has severe aortic stenosis presenting with;

    1. Critical aortic valve area defined as an initial aortic valve area of ≤1.0cm2 or aortic valve area index < 0.6cm2/m2 AND
    2. Mean gradient > 40mmHg or Vmax > 4m/sec by resting echocardiogram or simultaneous pressure recordings at cardiac catherization [or with dobutamine stress, if subject has left ventricular ejection fraction (LVEF) <55%] or velocity ratio < 0.25;
  • Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater;
  • Subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits;
  • Subject meets the legal minimum age to provide informed consent based on local regulatory requirements;

Exclusion Criteria:

  • Subject has refused surgical aortic valve replacement (SAVR) as a treatment option; (not applicable for Single Arm)
  • Any condition considered a contraindication for placement of a bioprosthetic valve (i.e., subject requires a mechanical valve);
  • A known hypersensitivity or contraindication to all anticoagulation/antiplatelet regimens (or inability to be anticoagulated for the index procedure), nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated;
  • Blood dyscrasias as defined: leukopenia (WBC <1000mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy;
  • Ongoing sepsis, including active endocarditis;
  • Any condition considered a contraindication to extracorporeal assistance;
  • Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to randomization* (Subjects with recent placement of drug eluting stent(s) should be assessed for ability to safely proceed with SAVR within the protocol timeframe);
  • Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within six weeks of randomization*;
  • Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support;
  • Recent (within 6 months of randomization*) cerebrovascular accident (CVA) or transient ischemic attack (TIA);
  • Active gastrointestinal (GI) bleeding that would preclude anticoagulation;
  • Subject refuses a blood transfusion;
  • Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits);
  • Multivessel coronary artery disease with a Syntax score >22 and/or unprotected left main coronary artery (Syntax score calculation is not required for patients with history of previous revascularization if repeat revascularization is not planned);
  • Estimated life expectancy of less than 24 months due to associated non-cardiac comorbid conditions;
  • Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams;
  • Currently participating in an investigational drug or another device trial (excluding registries);
  • Evidence of an acute myocardial infarction ≤30 days before the index procedure;
  • Need for emergency surgery for any reason;
  • True porcelain aorta (i.e. Heart Team agrees the aorta is not clampable for SAVR);
  • Extensive mediastinal radiation;
  • Liver failure (Child-C);
  • Reduced ventricular function with left ventricular ejection fraction (LVEF) <20% as measured by resting echocardiogram;
  • Uncontrolled atrial fibrillation (e.g. resting heart rate > 120 bpm);
  • Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements;
  • End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min;
  • Pulmonary Hypertension (systolic pressure> 80mmHg);
  • Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by Forced Expiratory Volume (FEV1) < 750cc;
  • Frailty assessments identify:

    1. Subject is < 80 years of age and three or more of the following apply
    2. Subject is ≥ 80 years of age and two or more of the following apply

      • Wheelchair bound
      • Resides in an institutional care facility (e.g., nursing home, skilled care center)
      • Body Mass Index < 20 kg/m2
      • Grip Strength < 16 kg
      • Katz Index Score ≤ 4
      • Albumin < 3.5 g/dL;
  • Marfan syndrome or other known connective tissue disease that would necessitate aortic root replacement/intervention; (Not applicable for Single Arm)

Note: Additional anatomical and vascular exclusion criteria may apply.

Note: * For purposes of the single arm phase of the trial, "randomization" will refer to trial enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01586910

  Hide Study Locations
United States, Arizona
Banner Good Samaritan Medical Center
Phoenix, Arizona, United States, 85006
United States, California
Cedars-Sinai Medical Center
Hollywood, California, United States, 90048
Scripps Green Hospital
La Jolla, California, United States, 92037
Keck Medical Center of USC
Los Angeles, California, United States, 90033
El Camino Hospital
Mountain View, California, United States, 94040
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304
Southern California Permenente Medical Group
Pasadena, California, United States, 91101
Stanford University Medical Center
Stanford, California, United States, 94305
United States, Connecticut
Hartford Hospital
Hartford, Connecticut, United States, 06102
Yale New Haven Hospital
New Haven, Connecticut, United States, 06520-8047
United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20010
United States, Florida
Morton Plant Hospital
Clearwater, Florida, United States, 33756
University of Miami
Coral Gables, Florida, United States, 33146
Delray Medical Center
Delray Beach, Florida, United States, 33484
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30308
Piedmont Healthcare, Inc.
Atlanta, Georgia, United States, 30309
United States, Hawaii
The Queen's Medical Center
Honolulu, Hawaii, United States, 96813
United States, Illinois
Loyola University of Chicago
Maywood, Illinois, United States, 60153
United States, Indiana
St. Vincent Heart Center of Indiana
Indianapolis, Indiana, United States, 46290
United States, Iowa
Iowa Heart Center / Mercy Medical Center
West Des Moines, Iowa, United States, 50266
United States, Kansas
University of Kansas Hospital
Kansas City, Kansas, United States, 66160
United States, Louisiana
Cardiovascular Institute of the South
Houma, Louisiana, United States, 70360
United States, Maryland
The Johns Hopkins University
Baltimore, Maryland, United States, 21205
United States, Massachusetts
Beth Israel Deaconess Medical Center, Inc.
Boston, Massachusetts, United States, 02215
United States, Michigan
University of Michigan Health Systems
Ann Arbor, Michigan, United States, 48109-5864
Detroit Medical Center
Detroit, Michigan, United States, 48201-2018
Henry Ford
Detroit, Michigan, United States, 48202
St. John Hospital & Medical Center
Detroit, Michigan, United States, 48236
Spectrum Health Hospitals
Grand Rapids, Michigan, United States, 49503
United States, Minnesota
Abbott NW - MN Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
Mayo Clinic - St. Mary's Hospital
Rochester, Minnesota, United States, 55905
United States, Missouri
Saint Luke's Hospital/MAHI
Kansas City, Missouri, United States, 64111
United States, Nebraska
Alegent Creighton Health Research Center
Omaha, Nebraska, United States, 68124
United States, New Jersey
Cooper University Hospital
Camden, New Jersey, United States, 08103
Morristown Medical Center
Morristown, New Jersey, United States, 07960
United States, New York
North Shore University Hospital
Manhasset, New York, United States, 11030
Winthrop University Hospital
Mineola, New York, United States, 11501
New York University School of Medicine
New York, New York, United States, 10016
Mount Sinai School of Medicine
New York, New York, United States, 10029
Columbia University Medical Center
New York, New York, United States, 10032
Lenox Hill Hospital
New York, New York, United States, 10075
University of Rochester
Rochester, New York, United States, 14642
St. Francis Hospital
Roslyn, New York, United States, 11576
United States, North Carolina
Carolinas HealthCare System
Charlotte, North Carolina, United States, 28203
Duke University Medical Center
Durham, North Carolina, United States, 27710
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Good Samaritan Hospital
Cincinnati, Ohio, United States, 45220
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
The Ohio State University
Columbus, Ohio, United States, 43210
The OhioHealth Research Institute
Columbus, Ohio, United States, 43214
United States, Oklahoma
Oklahoma Heart Institute
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Geisinger Medical Center
Danville, Pennsylvania, United States, 17822
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States, 19104
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Pinnacle Health Cardiovascular Institute
Wormleysburg, Pennsylvania, United States, 17043
United States, Tennessee
Baptist Memorial Hospital Memphis
Memphis, Tennessee, United States, 38120
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor Heart and Vascular Hospital
Dallas, Texas, United States, 75226
The Methodist DeBakey Heart & Vascular Center
Houston, Texas, United States, 77030
The Heart Hospital - Baylor Plano
Plano, Texas, United States, 75093
United States, Utah
Intermountain Medical Center
Murray, Utah, United States, 84107
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05401
United States, Virginia
Sentara Cardiovascular
Norfolk, Virginia, United States, 23507
Bon Secours St. Mary's Hospital
Richmond, Virginia, United States, 23226
United States, Wisconsin
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States, 53215
Canada, Ontario
London Health Sciences Centre, University Hospital
London, Ontario, Canada
Sunnybrook Research Institute
Toronto, Ontario, Canada, M4N 3M5
Toronto General Hospital (University Health Network)
Toronto, Ontario, Canada, M5G 2C4
Canada, Quebec
McGill University Health Center - Royal Victoria Hospital
Montreal, Quebec, Canada, H3A 1A1
Montreal Heart Institute
Montreal, Canada
Copenhagen, Denmark
Universitäts-Herzzentrum Freiburg • Bad Krozingen
Bad Krozingen, Germany, 79106
Universitätsklinikum Bonn
Bonn, Germany
Deutsches Herzzentrum Muenchen
Munich, Germany
Amphia Hospital Breda
Breda, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, Netherlands
St. Antonius Hospital, R & D Cardiology
Nieuwegein, Netherlands
Erasmus Medical Center - Rotterdam
Rotterdam, Netherlands
Servicio de Cardiologia del Hospital Virgen de la Victoria
Malaga, Spain
Hospital Universitario Central de Asturias
Oviedo, Spain
Karolinska Universitetssjukhuset Stockholm
Stockholm, Sweden, 171 76
Bern University Hospital
Bern, Switzerland
Universitatsspital Zurich
Zurich, Switzerland
United Kingdom
Leeds General Infirmary
Leeds, United Kingdom
Glenfield Hospital, Leicester, UK
Leicester, United Kingdom, LE5 4PW
St. George's Hospital London
London, United Kingdom, SW170QT
Sponsors and Collaborators
Medtronic Cardiovascular
Principal Investigator: Stephan Windecker, MD, PhD Bern University Hospital
Principal Investigator: A. Pieter Kappetein, MD, PhD Erasmus Medical Center
Principal Investigator: Rüdiger Lange, MD, PhD Deutsches Herzzentrum München
Principal Investigator: Thomas Walther, MD, PhD Kerckhoff Klinik
Principal Investigator: Jeffrey J. Popma, MD Beth Israel Deaconess Medical Center
Principal Investigator: Michael J. Reardon, MD The Methodist Hospital System
Principal Investigator: David H. Adams, MD Icahn School of Medicine at Mount Sinai
Study Chair: Nicolas M. Van Mieghem, MD Erasmus Medical Center
Study Chair: Patrick W. Serruys, MD, PhD National Heart & Lung Institute of Imperial College in London

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medtronic Cardiovascular Identifier: NCT01586910     History of Changes
Other Study ID Numbers: IDE #G120169
First Posted: April 27, 2012    Key Record Dates
Last Update Posted: April 27, 2018
Last Verified: April 2018

Additional relevant MeSH terms:
Constriction, Pathologic
Aortic Valve Stenosis
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction